Cargando…
Socioeconomic aspects of incretin-based therapy
Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have demonstrated cardiovascular benefits in people with type 2 diabetes. However, socioeconomic disparities in their uptake may constrain the collective advantages offered by these medications to the broad...
Autores principales: | Karagiannis, Thomas, Bekiari, Eleni, Tsapas, Apostolos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474181/ https://www.ncbi.nlm.nih.gov/pubmed/37433896 http://dx.doi.org/10.1007/s00125-023-05962-z |
Ejemplares similares
-
Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy
por: Karagiannis, Thomas, et al.
Publicado: (2017) -
Management of type 2 diabetes in the new era
por: Liakos, Aris, et al.
Publicado: (2023) -
Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos, Ioannis, et al.
Publicado: (2019) -
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
por: Karagiannis, Thomas, et al.
Publicado: (2022) -
Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis
por: Bekiari, Eleni, et al.
Publicado: (2018)